MARK L. FAUPEL, PH.D. - Corporate Board Profile

GUIDED THERAPEUTICS INC

Filing Date	Source Excerpt
2008-11-19	Mark L. Faupel, Ph.D. has been our President, Chief Executive Officer, Acting Chief Financial Officer and a member of our board of directors since 2007. ... Dr. Faupel's 2007 compensation consisted of a base salary of $160,000 and usual and customary company benefits.
2010-02-03	- Mark L. Faupel, Ph.D. is listed as President and Chief Executive Officer, Director in the proxy statement dated February 3, 2010.
2010-04-20	Mark L. Faupel, Ph.D. 54; has been a director since 2007 and has more than 25 years of experience in developing non-invasive alternatives to surgical biopsies and blood tests, especially in the area of cancer screening and diagnostics. Dr. Faupel has served as our Chief Executive Officer since May 2007 and prior thereto was our Chief Technical Officer from April 2001 to May 2007. Dr. Faupel’s 2009 and 2008 compensation consisted of a base salary of $228,000 and usual and customary company benefits. In 2009, Dr. Faupel received no bonus and 1.0 million incentive stock options. Dr. Faupel did not receive any stock options in 2008. Total compensation in 2009 was $608,000.
2011-06-30	Mark L. Faupel, Ph.D. has been a director since 2007 and has more than 25 years of experience in developing non-invasive alternatives to surgical biopsies and blood tests, especially in the area of cancer screening and diagnostics. Dr. Faupel has served as our Chief Executive Officer since May 2007 and prior thereto was our Chief Technical Officer from April 2001 to May 2007. Prior to coming to us in 1998, Dr. Faupel was the co-founder and Vice President of Research and Development at Biofield Corp. His work in early stage cancer detection has won two international awards and he is a former member of the European School of Oncology Task Force. Dr. Faupel serves as a National Institutes of Health reviewer, is the inventor on 15 U.S. patents and has authored numerous scientific publications and presentations, appearing in such peer-reviewed journals as The Lancet. Dr. Faupel earned his Ph.D. in neuroanatomy and physiology from the University of Georgia. Dr. Faupel’s extensive experience in founding and managing point of care cancer detection companies includes the basic scientific applications, clinical trials, regulatory affairs and financing. As such, Dr. Faupel is uniquely qualified to advise the board on all aspects of our business. Dr. Faupel’s 2010 and 2009 compensation consisted of a base salary of $228,000 and usual and customary company benefits. In 2009, Dr. Faupel received no bonus and 1 million incentive stock options. Incentive stock options granted to employees, officers and directors under the Company’s Stock Based Compensation Plan are exercisable for a period of up to 10 years from the date of grant, at an exercise price that is not less than the fair market value of the common stock on the date of the grant. The options vest in three installments: One-third of the options vest equally over a two year period; one-third vest upon a certain condition that was met as of December 31, 2009; and the remaining one-third vest when a certain condition is achieved. The condition had not been met as of December 31, 2010. In December 2010, Dr Faupel was issued 100,000 shares of common stock, as a payment for a portion of his outstanding deferred salary of $82,000, the value of our common stock on the date of issuance. As of December 31, 2010, Dr. Faupel’s remaining deferred salary was approximately $299,414. On March 22 and May 27, 2010, Dr. Faupel was issued 250,000 options each, to purchase common stock at $1.33 and $0.75, respectively, pursuant to his employment agreement.
2012-04-30	Mark L. Faupel, Ph.D. 56 Chief Executive Officer, Acting Chief Financial Officer, President and Director... Dr. Faupel’s 2011 and 2010 compensation consisted of a base salary of $243,000 and $228,000, respectively... In 2011, 130,000 options to purchase common stock at $1.47 were issued to him.
2013-04-26	Mark L. Faupel, Ph.D. has been a director since 2007 and has more than 26 years of experience... Dr. Faupel has served as our Chief Executive Officer since May 2007 and prior thereto was our Chief Technical Officer from April 2001 to May 2007. He is currently our Acting Chief Financial Officer as well... Dr. Faupel's 2012 and 2011 compensation consisted of a base salary of $243,000, and usual and customary company benefits.
2018-09-17	Mark L. Faupel, Ph.D., rejoined us as Chief Operating Officer and director on December 8, 2016. He previously served on our Board through 2013 and has more than 30 years of experience in developing non-invasive alternatives to surgical biopsies and blood tests, especially in the area of cancer screening and diagnostics. Dr. Faupel was one of our co-founders and also served as our Chief Executive Officer from May 2007 through 2013. Prior thereto was our Chief Technical Officer from April 2001 to May 2007. Dr. Faupel has served as a National Institutes of Health reviewer, is the inventor on 26 U.S. patents and has authored numerous scientific publications and presentations, appearing in such peer-reviewed journals as The Lancet. Dr. Faupel earned his Ph.D. in neuroanatomy and physiology from the University of Georgia. Dr. Faupel is also a shareholder of Shenghuo Medical, LLC.
2018-10-11	Mark L. Faupel, Ph.D. (*), 62, Chief Operating Officer and Director. For the fiscal years ended December 31, 2017 and 2016, none of our directors received any form of compensation.
2021-07-06	Mark L. Faupel, Ph.D., rejoined us as Chief Operating Officer and director on December 8, 2016. ... For the fiscal years ended December 31, 2020 and 2019, none of our directors received any form of cash compensation. ... 2020 and 2019 Summary Compensation Table ... Mark L. Faupel, Ph.D. COO and Director ... Total ($) 219,200.